Rakovina Therapeutics Boosts Investor Access with DTC Eligibility
Vancouver, British Columbia—Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a trailblazer in biopharmaceuticals known for its pioneering work in cancer therapies through AI-driven drug discovery, is thrilled to announce that its shares have obtained eligibility for electronic clearing and settlement via The Depository Trust Company (DTC).
This pivotal DTC eligibility significantly simplifies the trading process for U.S. investors, thereby enhancing liquidity and expanding the market’s accessibility for Rakovina shares. The DTC, a key component of the Depository Trust & Clearing Corporation (DTCC), represents the largest securities depository globally, ensuring a seamless settlement process for major U.S. stock exchanges.
“Achieving DTC eligibility marks a significant milestone for Rakovina as it considerably boosts both our visibility and accessibility among a wider range of institutional and retail investors,” stated Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “By eliminating a crucial barrier to efficient trading in the U.S. market, we not only enhance liquidity but also lay the groundwork for deeper engagement with U.S. capital markets as we follow through with our ambitious growth strategy.”
Strategic Growth and Value for Shareholders
The designation paves the way for U.S. investors by allowing the trading of Rakovina shares electronically, which, in turn, reduces transaction costs and processing downtime. This advancement aligns with the company’s objective to boost market participation and ultimately deliver enduring value to its shareholders.
With DTC eligibility announced, Rakovina continues to push forward with its preclinical programs while actively seeking strategic partnerships in the areas of AI-enhanced diagnostics and oncology therapeutics. As the company builds on its current momentum, additional corporate developments are anticipated in the near future as it executes its strategic roadmap.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is committed to developing cutting-edge cancer treatments, using innovative technologies centered around the DNA-damage response, powered by Artificial Intelligence (AI) through proprietary platforms such as Deep-Docking™ and Enki™. The company leverages AI to accelerate the evaluation and optimization of drug candidates at unprecedented speeds.
The robust pipeline established by Rakovina includes a unique array of DNA-damage response inhibitors, with the aspiration to advance one or several drug candidates into human clinical trials in collaboration with pharmaceutical partners who share its vision.
Contact Information
For more details, please reach out to:
Michelle Seltenrich, BSc MBA
Director, Corporate Development
Email: IR@rakovinatherapeutics.com
Phone: 778-773-5432
Frequently Asked Questions
What is DTC eligibility, and why is it important?
DTC eligibility allows Rakovina Therapeutics shares to be electronically traded, simplifying the trade process for U.S. investors and enhancing market liquidity.
How does DTC eligibility impact Rakovina's growth strategy?
By removing barriers to trading, DTC eligibility facilitates greater engagement with the U.S. capital markets, supporting Rakovina's broader growth strategy.
What are the core focus areas for Rakovina Therapeutics?
Rakovina focuses on developing innovative cancer therapies, particularly through AI-enhanced drug discovery and targeting DNA-damage response.
Who can I contact for more information about Rakovina Therapeutics?
You can contact Michelle Seltenrich, the Director of Corporate Development, via email at IR@rakovinatherapeutics.com or by phone at 778-773-5432.
What is the significance of AI in Rakovina’s drug discovery process?
AI significantly accelerates the drug discovery process, allowing Rakovina to optimize potential drug candidates more quickly than traditional methods.
